<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03117101</url>
  </required_header>
  <id_info>
    <org_study_id>CL1-80881-005</org_study_id>
    <nct_id>NCT03117101</nct_id>
  </id_info>
  <brief_title>Study of the AL3810 in the Treatment of Advanced Solid Tumor</brief_title>
  <official_title>An Open-label, Dose-finding Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, Pharmacodynamics of the Dual -VEGFR-FGFR Tyrosine Kinase Inhibitor, AL3810, Givenorally as Single Agent to Patients With Advanced Solid Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haihe Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Institute of Materia Medica, Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Haihe Biopharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I&#xD;
      study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology:&#xD;
&#xD;
      This was a monocentric, open label, non-randomised, non-comparative, dose-finding phase I&#xD;
      study with a traditional 3+3 design, conducted in Chinese patients with advanced solid&#xD;
      tumours without an established therapeutic alternative.This study was performed in strict&#xD;
      accordance with Good Clinical Practice including the archiving of essential documents.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identify Dose-limiting toxicity (DLT)</measure>
    <time_frame>35 days</time_frame>
    <description>To assess the tolerability of AL3810 in patients with advanced solid tumors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify maximum tolerated dose (MTD)</measure>
    <time_frame>35 days</time_frame>
    <description>To assess the tolerability of AL3810 in patients with advanced solid tumors</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum plasma concentration)</measure>
    <time_frame>Day0,Day8,Day15,Day22,Day29,Day57</time_frame>
    <description>Metabolism profiling of AL3810 and its potential metabolites in plasma The potential food interaction on metabolism profile of AL 3810 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax (time to maximum plasma concentration)</measure>
    <time_frame>Day0,Day8,Day15,Day22,Day29,Day57</time_frame>
    <description>Metabolism profiling of AL3810 and its potential metabolites in plasma The potential food interaction on metabolism profile of AL 3810 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (area under the plasma concentration-time curve)</measure>
    <time_frame>Day0,Day8,Day15,Day22,Day29,Day57</time_frame>
    <description>Metabolism profiling of AL3810 and its potential metabolites in plasma The potential food interaction on metabolism profile of AL 3810 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10.CBR (clinical benefit rate)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Tumor will be evaluated according to RECIST-1.1. CT or MRI can be used for tumor imaging at the investigator's discretion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose escalation/ Dose extension of Lucitanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation: Dose Level -1: 5 mg.Dose Level 1:.10 mg.Dose Level 2: 15 mg.Dose Level 3: 20 mg.&#xD;
Dose extension: Once the MTD was reached, the MTD-5 mg dose level was to be extended in order to enrol up to 12 patients (number of patients was to be determined regarding safety data) to better assess the toxicity profile, PK profile and antitumor activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lucitanib</intervention_name>
    <arm_group_label>Dose escalation/ Dose extension of Lucitanib</arm_group_label>
    <other_name>AL3810</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chinese male or female patient aged ≥ 18 years old and ≤ 70 years old.&#xD;
&#xD;
          2. Estimated life expectancy ≥ 12 weeks.&#xD;
&#xD;
          3. Histologically or cytologically confirmed, locally advanced or metastatic solid tumor,&#xD;
             refractory to standard therapy or no standard therapy available.&#xD;
&#xD;
          4. Full recovery (to grade ≤ 1) from any prior surgical procedure(s) and from reversible&#xD;
             side effects of prior therapy for cancer including radiation therapy, chemotherapy,&#xD;
             small molecule therapeutics and immunotherapy.&#xD;
&#xD;
          5. Patients should be evaluable according to RECIST criteria, version 1.1.&#xD;
&#xD;
          6. Adequate haematological, hepatic and renal functions:&#xD;
&#xD;
             Absolute neutrophil count (ANC) ≥ 1.5x 10^9/L Platelet counts ≥ 100 x 10^9/L.&#xD;
             Haemoglobin ≥ 9 g/dL. Creatinine clearance &gt; 50 mL/min (assessed with MDRD formula).&#xD;
             Proteinuria qualitative test &lt; 1+. If proteinuria qualitative test ≥ 1+, proteinuria&#xD;
             over 24 hours should be &lt; 1.0 g/24hrs.&#xD;
&#xD;
             INR ≤ 1.5. AST, ALT ≤ 1.5 x Upper Limit of Normal Value (ULN) (≤ 3 x ULN in case of&#xD;
             liver metastasis).&#xD;
&#xD;
             Bilirubin &lt; 1.5 x ULN.&#xD;
&#xD;
          7. Eastern Co-operative Group (ECOG) performance status ≤ 1.&#xD;
&#xD;
          8. Ability to swallow oral capsules.&#xD;
&#xD;
          9. Negative serum pregnancy test at screening in women of childbearing potential within 7&#xD;
             days prior the study drug intake.&#xD;
&#xD;
         10. Willingness and ability to comply with study procedures.&#xD;
&#xD;
         11. Signed written Informed Consent Form.&#xD;
&#xD;
             Exclusion Criteria:&#xD;
&#xD;
         12. Participation in another therapeutic clinical trial at the same time or within 4 weeks&#xD;
             prior to first AL3810 intake. In case of involvement in a non-interventional clinical&#xD;
             trial (e.g. epidemiological study), inclusion in the present study is possible.&#xD;
&#xD;
         13. Foreseeable poor compliance to the study procedures.&#xD;
&#xD;
         14. Known active central nervous system (CNS) metastases not controlled by prior surgery&#xD;
             or radiotherapy and/or low dose steroids.&#xD;
&#xD;
         15. Active second malignancy or history of other malignancy within 2 years, with the&#xD;
             exception of non-melanoma skin cancers or carcinoma in situ (CIS) of the breast or&#xD;
             cervix or controlled, superficial carcinoma of the bladder.&#xD;
&#xD;
         16. Chemotherapy including biologic/targeted therapy or immunological agents within 4&#xD;
             weeks or 5 half-lives of the agent, whichever the longest, before inclusion.&#xD;
&#xD;
         17. Previous treatment with bevacizumab within 3 months before the first day of AL3810&#xD;
             administration.&#xD;
&#xD;
         18. Patients who received radiotherapy within 4 weeks of starting study treatment.&#xD;
&#xD;
         19. Major surgery within 4 weeks before first day of study drug administration.&#xD;
&#xD;
         20. History of clinically significant or uncontrolled cardiac disease, including&#xD;
             congestive heart failure (New York Heart Association functional classification ≥ 3),&#xD;
             angina, myocardial infarction or ventricular arrhythmia.&#xD;
&#xD;
         21. Significant cardiovascular disease or condition, including:&#xD;
&#xD;
             Congestive heart failure requiring therapy. Ventricular and/or supra-ventricular&#xD;
             arrhythmia requiring therapy. Severe conduction disturbance (including QTc interval&#xD;
             prolongation &gt; 450 msec [corrected], history of severe arrhythmia, or history of&#xD;
             familial arrhythmia [e.g., Wolff-Parkinson-White syndrome]).&#xD;
&#xD;
             Angina pectoris requiring therapy. Left ventricular ejection fraction (LVEF) &lt; 50%&#xD;
             evaluated by cardiac ultrasound (ECHO) or Multi Gated Acquisition Scan (MUGA).&#xD;
&#xD;
             Myocardial infarction (MI) within 6 months prior to administration of the first dose.&#xD;
&#xD;
             Cardiovascular disease &gt; Class I, according to the New York Heart Association's (NYHA)&#xD;
             Functional Criteria.&#xD;
&#xD;
             Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 140mmHg&#xD;
             and/or diastolic blood pressure ≥ 90mmHg with optimized antihypertensive therapy or&#xD;
             patients treated with ≥2 antihypertensive agents) or systolic blood pressure ≥ 160mmHg&#xD;
             and/or diastolic blood pressure ≥ 100mmHg with or without antihypertensive therapy.&#xD;
&#xD;
         22. Patients with thromboembolic events &lt; 12 months prior to treatment start or at high&#xD;
             risk of such events.&#xD;
&#xD;
         23. Ongoing treatment with warfarin or other oral anticoagulant.&#xD;
&#xD;
         24. Unavoidable concomitant treatment with any drug known for potential risk of causing&#xD;
             Torsades de Pointes.&#xD;
&#xD;
         25. Serum potassium (K+) levels below LLN or 3.0 mmol/L at screening.&#xD;
&#xD;
         26. Patients who received administration of strong inhibitors of CYP2C8 and/or CYP3A4 or&#xD;
             strong inducers of CYP3A4 within 7 days before the first dose of AL3810 or have&#xD;
             on-going requirements for these medications (appendix 15).&#xD;
&#xD;
         27. Significant gastrointestinal abnormalities, including ulcerative colitis, chronic&#xD;
             diarrhoea associated with intestinal malabsorption, Crohn's disease, or decided by&#xD;
             investigator.&#xD;
&#xD;
         28. Known pre-existing clinically significant disorder of the hypothalamic-pituitary axis,&#xD;
             thyroid and adrenal gland.&#xD;
&#xD;
         29. Serious/active bacterial, viral or fungal infection (including known active human&#xD;
             immunodeficiency virus [HIV] infection) requiring systemic treatment.&#xD;
&#xD;
         30. Concomitant uncontrolled severe systemic disease (e.g., uncontrolled diabetes&#xD;
             mellitus, etc.).&#xD;
&#xD;
         31. Psychiatric disorder or altered mental status that would preclude understanding of the&#xD;
             informed consent process and/or completion of the necessary study procedures.&#xD;
&#xD;
         32. Known organ dysfunction which would either compromise the patient's safety or&#xD;
             interfere with the evaluation of AL3810.&#xD;
&#xD;
         33. Men and women of child bearing potential unable or unwilling to employ effective&#xD;
             contraception (abstinence, barrier method with spermicide, intrauterine device, or&#xD;
             steroidal contraceptive for women and barrier method) during the study and for 6&#xD;
             months thereafter.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junning Cao, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>April 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2017</study_first_posted>
  <last_update_submitted>April 14, 2017</last_update_submitted>
  <last_update_submitted_qc>April 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

